Back to top
more

SYNTHORX INC. - COMMON STOCK (THOR)

(Delayed Data from NSDQ)

$16.99 USD

16.99
22,923

-2.21 (-11.52%)

Updated Jan 22, 2020 03:57 PM ET

Add to portfolio

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.13%
17.51%
9.18%
4.92%
1.66%
10.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

NA Value | NA Growth | NA Momentum | NA VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Can Winnebago Replicate This Year's Stellar Show in 2020?

Winnebago (WGO) looks well poised to maintain this year's momentum in the New Year, courtesy of its leadership position in the industry, game-changing acquisitions and solid financials.

WGO SKY THOR LCII

Sweta Killa

Biotech Leading in Q4: Best ETFs & Stocks

We highlight five biotech ETFs and stocks that are leading the market in Q4.

SNY MRK RHHBY NVS CNCR SBIO XBI BBC THOR SRPT GBT VRTX AXSM CLSD

Zacks Equity Research

Moving Average Crossover Alert: Synthorx

Synthorx, Inc. (THOR) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

THOR

Neena Mishra

Why Biotech ETFs are Surging to New Highs

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

MRK SNY NVS IBB BBC SBIO XBI THOR MDCO ARQL AUPH ARKG

Sweta Killa

Biotech ETFs Hit New Highs on Deal Activities

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

AGN SNY ABBV MRK BMY IBB CNCR BBC XBI SBIO THOR AMGN CELG ARQL G

Zacks Equity Research

Company News for Dec 10, 2019

Companies in the news are: ARQL, THOR, CGC, FATE

THOR FATE ARQL CGC

Zacks Equity Research

Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research

Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.

SNY NVS THOR REGN

Kinjel Shah

Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms

Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.

SNY MRK THOR ARQL

Zacks Equity Research

Week Begins with Biotech Mergers

Week Begins with Biotech Mergers

SNY MRK RHHBY THOR ONCE ARQL

Mark Vickery

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

MRK RHHBY SNY THOR ONCE ARQL

Zacks Equity Research

Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio

Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.

SNY ABBV BMY THOR

Zacks Equity Research

Will Synthorx Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Synthorx.

THOR

Zacks Equity Research

Synthorx's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Synthorx.

THOR